Therapy News and Research

RSS

Dabigatran ‘still effective in obese’

The oral direct thrombin inhibitor dabigatran is an effective thromboprophylactic therapy for patients undergoing total hip or knee replacement regardless of their body mass index, researchers assert.

9 Aug 2012

Loyola to offer new radiotherapy system for cancer patients

A new radiotherapy system at Loyola University Medical Center will offer cancer patients shorter radiation treatments, with pinpoint accuracy and precision.

9 Aug 2012

Clinical trials to test safety of 3K3A-APC in patients with ischemic stroke

Clinical trials start this week for a stroke drug initially created by a team led by scientists at The Scripps Research Institute and the University of Southern California (USC), and further developed by biotech company ZZ Biotech.

9 Aug 2012

Novel model may allow clinicians to predict potential for recovery after SCI

For more than 1 million people in the U.S. living with spinal cord injury, the frightening days and weeks following the injury are filled with uncertainty about their potential for recovery and future independence. A new model based on motor scores at admission and early imaging studies may allow clinicians to predict functional outcomes and guide decision-making for therapy and care-giving needs, as described in an article published in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

9 Aug 2012

Combination of two existing pharmaceutical drugs shows promise against cocaine addiction

A fine-tuned combination of two existing pharmaceutical drugs has shown promise as a potential new therapy for people addicted to cocaine—a therapy that would reduce their craving for the drug and blunt their symptoms of withdrawal.

9 Aug 2012

Study identifies a switch in cells that may help to kill tumors with heat

Research at Bangor University has identified a switch in cells that may help to kill tumors with heat. Prostate cancer and other localized tumors can be effectively treated by a combination of heat and an anti-cancer drug that damages the genes. Behind this novel therapy is the enigmatic ability of heat to switch off essential survival mechanisms in human cells. Although thermotherapy is now more widely used, the underlying principles are still unclear.

9 Aug 2012

Theranostic imaging targets and tracks potent drug therapies to prostate cancer cells

Experimenting with human prostate cancer cells and mice, cancer imaging experts at Johns Hopkins say they have developed a method for finding and killing malignant cells while sparing healthy ones.

9 Aug 2012

Researchers develop and test new prostate cancer screening method

Researchers have successfully developed and tested a new prostate cancer screening method that uses the combined power of a novel drug therapy and changes in PSA levels over time to identify men with a high PSA who are more likely to have aggressive prostate cancer despite negative biopsies.

9 Aug 2012

MedPage Today, CollabRx sign license agreement for Oncology Next

Tegal Corporation today announced that its recently acquired CollabRx, Inc., subsidiary signed an exclusive license agreement to provide a version of its proprietary Therapy Finder tool to MedPage Today, Everyday Health, Inc.'s rapidly growing online site that serves 96% of all oncologists and 1.6 million monthly online unique users.

9 Aug 2012

Berlin Heart EXCOR Pediatric Ventricular Assist Device proves effective and life-saving

A tiny heart pump that maintains blood flow in babies and small children with serious heart failure proved effective and life-saving in a pioneering study involving 17 institutions led by Texas Children's Hospital and Baylor College of Medicine (BCM).

9 Aug 2012

Cardionovum to introduce PROLIMUS Biograde system in Europe

Cardionovum GmbH announced today that it expects to launch in Europe in Q4 2012 a next-generation Sirolimus-eluting coronary stent system—PROLIMUS Biograde—which is designed to optimize long-term patient results. Unlike many state-of-the-art DES that are currently being marketed, PROLIMUS Biograde provides multiple pro-healing product features to promote early re-endothelialization.

9 Aug 2012

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).

9 Aug 2012

FDA approves Codman’s MEDSTREAM Programmable Infusion System

Codman & Shurtleff, Inc. (Codman), the global neurological device company, has received U.S. Food and Drug Administration (FDA) approval through a PMA supplement for its MEDSTREAM Programmable Infusion System, an implantable infusion pump and catheter system used in the treatment of spasticity, a movement disorder often caused by stroke, cerebral palsy, multiple sclerosis or spinal cord injury.

9 Aug 2012